Santalis announces positive results for pediatric atopic dermatitis treatment

Santalis Pharmaceuticals announced in a press release positive preliminary results from an expanded study of its Santalia AD product regimen for treating pediatric atopic dermatitis.

The over-the-counter products contain East Indian sandalwood oil and colloidal oatmeal, according to the release. The study was conducted on 25 patients, aged 3 months to 12 years, with mild, moderate or severe atopic dermatitis with a mean beginning Eczema Area and Severity Index (EASI) score of 11.1 or moderate.

Patients were instructed to apply the Santalia AD regimen cleanser and cream twice daily for 60 days, and use the regimen’s bubble bath at least three times a week, according to the release. Twenty-two patients completed with study, with 82% of those patients meeting primary efficacy endpoint of a 25% reduction in EASI, the release reported. There was a 60% reduction in EASI score over baseline in all patients.

There were 78.9% of patients who reported a reduction in redness and an improvement in skin texture in the treated area, while 73.7% reported improvement in pain or irritation in the treatment area, according to the release.

No adverse events were found to be related to the study drug, and the Santalia AD was generally safe and well-tolerated, the release reported.

“The results seen were better than had previously been achieved by these patients from the use of other topical treatments, including both over-the-counter and prescription drugs,” John Browning, MD, assistant professor of pediatrics and dermatology at Baylor College of Medicine and chief of dermatology, stated in the release.

Santalis reported that it expects Santalia AD over-the-counter kit to be available for distribution in 2017.

Reference: Santalis Pharmaceuticals; www.businesswire.com